Search

everythinglearnresearchcommunity

for

Search:↓

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

MK-5108 is safe and shows potential against tumors, especially alone.

The combination treatment showed a higher response rate but no significant survival benefits.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Nano-Pulse Stimulation™ Therapy is more effective and less damaging than cryoablation for treating melanoma tumors in mice.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

3D imaging effectively tracks skin changes in vitiligo treatment.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

MVP treatment is effective and safe for recurrent breast cancer.

Imiquimod shows promise as a non-invasive treatment for certain HPV-related lesions, but more research is needed to optimize its use.

Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.

Imuvert can prevent some chemotherapy-induced hair loss.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.